0001497253false00014972532024-08-052024-08-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 05, 2024

 

 

Organovo Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35996

27-1488943

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

11555 Sorrento Valley Rd

Suite 100

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 224-1000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

ONVO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 5, 2024, (the “Grant Date”) Keith Murphy, the Executive Chairman of Organovo Holdings, Inc. (the Company”), was granted a time-based option to purchase 574,923 shares of common stock, which was equal to 4.0% of the outstanding shares of common stock on the Grant Date (the “Time-Based Option”) and a performance-based option to purchase 431,193 shares of common stock, which was equal to 7.0% of the outstanding shares of common stock on the Grant Date (the “Performance-Based Option” and, together with the Time-Based Option, the “Options”). The exercise price of the Options is $0.5368 per share. The Options were approved by the Compensation Committee of the Board of Directors of the Company on August 4, 2024 and were granted under the Company’s 2022 Equity Incentive Plan.

The Time-Based Option will vest over three years, with one-third of the total number of shares vesting on each successive anniversary of the grant, subject in each case to Mr. Murphy’s continued service to the Company on each vesting date. The Performance-Based Option will vest in tranches upon the achievement of certain revenue, market capitalization, stock price and strategic goals, subject in each case to Mr. Murphy’s continued service to the Company on each vesting date.

In addition, if the Company closes an equity financing (in one or more tranches) after the Grant Date and on or prior to March 31, 2025 (the “Financing”) and the aggregate number of shares of common stock issuable upon exercise of the Time-Based Option and the Performance-Based Option is equal to less than 4.0% and 7.0%, respectively, of the number of shares of common stock outstanding immediately after such Financing (in all cases assuming no exercise of any of the Options) (“Post-Financing Shares Outstanding”), Mr. Murphy will be granted: (a) an additional time-based option to purchase such number of shares of common stock as is equal to 4.0% of the Post-Financing Shares Outstanding minus the number of shares initially issuable upon exercise of the Time-Based Option (as adjusted for any stock split, stock dividend or similar change in the common stock occurring after the Grant Date), and/or (b) an additional performance-based option to purchase such number of shares of common stock as is equal to 7% of the Post-Financing Shares Outstanding minus the number of shares of Common Stock initially issuable upon exercise of the Performance-Based Option (as adjusted for any stock split, stock dividend or similar change in the Common Stock occurring after the Grant Date) ((a) and (b) collectively, the “True-Up Options”), each of which shall be subject to the vesting requirements (including the vesting commencement date) and substantially the same terms as the Time-Based Option and Performance-Based Option, respectively, other than that the exercise price for such True-Up Options shall be the closing price of the common stock on the date of grant, which shall be the date of the closing of the Financing.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Organovo Holdings, Inc.

 

 

 

 

Date:

August 9, 2024

By:

/s/ Keith Murphy

 

 

 

Name: Keith Murphy
Title: Executive Chairman

 


v3.24.2.u1
Document And Entity Information
Aug. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 05, 2024
Entity Registrant Name Organovo Holdings, Inc.
Entity Central Index Key 0001497253
Entity Emerging Growth Company false
Entity File Number 001-35996
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 27-1488943
Entity Address, Address Line One 11555 Sorrento Valley Rd
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 224-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol ONVO
Security Exchange Name NASDAQ

Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Organovo Charts.
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Organovo Charts.